

Performance (consolidated)

(¥ million)

	FY2019 (JGAAP)	FY2020 (IFRS)	FY2021 (IFRS)	FY2022 (IFRS)	FY2023 (IFRS)	FY2024 (IFRS)	FY2025 (IFRS) (estimated)
Revenue	116,637	121,859	137,484	144,175	148,255	160,232	170,000
Operating profit	21,668	27,202	32,948	30,049	33,295	35,450	33,000
Profit before tax	22,442	27,608	33,301	30,489	33,616	36,135	33,700
Profit attributable to owners of parent	16,866	19,540	24,986	22,812	25,851	32,558	26,300

February 9, 2026

(¥ million)

Brand name	Active Ingredient	Indications	Launch Date	Sales FY2023 (IFRS)	Sales FY2024 (IFRS)	Sales FY2025 (IFRS)	
						Apr.-Dec.	Annual (estimated)
Viltepso	viltolarsen	Duchenne muscular dystrophy	Japan May-2020 U.S. Aug-2020	17,530	21,782	15,877	21,200
(Japan)				(4,407)	(4,664)	(3,685)	(4,800)
(U.S.)				(13,123)	(17,117)	(12,192)	(16,400)
Upravi	selexipag	pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension	Nov-2016/ Aug-2021	12,918	14,971	13,188	17,300
Vyxeos	daunorubicin / cytarabine	high-risk acute myeloid leukemia	May-2024	-	5,139	4,562	6,000
Gazyva	obinutuzumab	CD20-positive follicular lymphoma/ CD20-positive chronic lymphocytic leukemia	Aug-2018/ Dec-2022	4,695	4,821	3,950	5,000
Fintepla	fenfluramine hydrochloride	seizures associated with Dravet syndrome/ seizures associated with Lennox-Gastaut syndrome	Nov-2022	377	2,067	3,098	4,200
Erleada	apalutamide	prostate cancer	May-2019	-	-	3,039	6,300
Vidaza	azacitidine	myelodysplastic syndrome/ acute myeloid leukemia	Mar-2011/ Mar-2021	10,383	5,109	2,624	3,200
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-2019	2,221	2,364	2,090	2,500
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-2010	3,927	2,728	1,846	2,200
Cialis	tadalafil	erectile dysfunction	Jul-2009	2,499	2,425	1,753	2,300
CAP-1002 (U.S.)	deramiocecl	Duchenne muscular dystrophy cardiomyopathy	Filed	-	-	-	-
Profit in co-promotion				8,658	9,170	7,082	9,000
Revenues from the licensing of industrial property rights				40,304	45,585	36,802	49,000
Pharmaceuticals				125,105	138,654	110,194	147,500
Functional Food				23,150	21,577	16,941	22,500
Revenue				148,255	160,232	127,135	170,000